EP3755716A4 - Anti-pd-1 antibodies and uses thereof - Google Patents

Anti-pd-1 antibodies and uses thereof Download PDF

Info

Publication number: EP3755716A4
Authority: EP; European Patent Office
Prior art keywords: antibodies
Prior art date: 2018-02-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP18907329.9A

Other languages

German (de)

French (fr)

Other versions

EP3755716A1 (en

Inventor

Yi Yang

Jingshu XIE

Chunyan DONG

Fang Yang

Chengyuan LU

Xiaodong Cheng

Yuelei SHEN

Jian Ni

Yanan GUO

Yunyun CHEN

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eucure Beijing Biopharma Co Ltd

Original Assignee

Eucure Beijing Biopharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-02-23

Filing date

2018-02-23

Publication date

2021-08-04

2018-02-23 Application filed by Eucure Beijing Biopharma Co Ltd filed Critical Eucure Beijing Biopharma Co Ltd

2020-12-30 Publication of EP3755716A1 publication Critical patent/EP3755716A1/en

2021-08-04 Publication of EP3755716A4 publication Critical patent/EP3755716A4/en

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP18907329.9A 2018-02-23 2018-02-23 Anti-pd-1 antibodies and uses thereof Pending EP3755716A4 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/CN2018/077016 WO2019161536A1 (en)	2018-02-23	2018-02-23	Anti-pd-1 antibodies and uses thereof

Publications (2)

Publication Number	Publication Date
EP3755716A1 EP3755716A1 (en)	2020-12-30
EP3755716A4 true EP3755716A4 (en)	2021-08-04

Family

ID=67686644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18907329.9A Pending EP3755716A4 (en)	2018-02-23	2018-02-23	Anti-pd-1 antibodies and uses thereof

Country Status (9)

Country	Link
US (3)	US11155625B2 (en)
EP (1)	EP3755716A4 (en)
JP (1)	JP7110369B2 (en)
KR (1)	KR102608723B1 (en)
CN (1)	CN112105642B (en)
AU (1)	AU2018409906B2 (en)
CA (1)	CA3091502A1 (en)
IL (1)	IL276675B2 (en)
WO (1)	WO2019161536A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE057559T2 (en)	2016-11-02	2022-06-28	Jounce Therapeutics Inc	Antibodies against PD-1 and their applications
MX2020005364A (en)	2017-11-24	2020-08-13	Eucure Beijing Biopharma Co Ltd	Anti-ox40 antibodies and uses thereof.
WO2020103885A1 (en)	2018-11-19	2020-05-28	Beijing Biocytogen Co., Ltd	Anti-pd-1 antibodies and uses thereof
WO2021091960A1 (en) *	2019-11-05	2021-05-14	Jounce Therapeutics, Inc.	Methods of treating cancer with anti-pd-1 antibodies
BR112023006989A2 (en) *	2020-10-14	2024-01-02	Eucure Beijing Biopharma Co Ltd	ANTI-PD-1/CD40 BIESPECIFIC ANTIBODIES AND USES THEREOF
US20250270320A1 (en) *	2020-12-10	2025-08-28	Eutilex Co., Ltd.	Anti-pd-1 antibody and uses thereof
AU2023329401A1 (en) *	2022-08-25	2025-01-23	Bright Biologics Llc	Multispecific antibodies and uses thereof
CN117050165B (en) *	2023-08-14	2025-03-25	三优生物医药(上海)有限公司	An antibody targeting monkeypox virus, its antigen-binding fragment and its use
CN121248771A (en) *	2024-11-07	2026-01-02	上海蓝鹊生物医药有限公司	An antibody and kit targeting human desmosome glycoprotein 2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014179664A2 (en) *	2013-05-02	2014-11-06	Anaptysbio, Inc.	Antibodies directed against programmed death-1 (pd-1)
WO2016092419A1 (en) *	2014-12-09	2016-06-16	Rinat Neuroscience Corp.	Anti-pd-1 antibodies and methods of use thereof
WO2017019846A1 (en) *	2015-07-30	2017-02-02	Macrogenics, Inc.	Pd-1-binding molecules and methods use thereof
WO2017058115A1 (en) *	2015-09-29	2017-04-06	Asia Biotech Pte. Ltd.	Pd-1 antibodies and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8508845D0 (en)	1985-04-04	1985-05-09	Hoffmann La Roche	Vaccinia dna
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en)	1987-02-07	1987-03-11	Al Sumidaie A M K	Obtaining retrovirus-containing fraction
WO1989001973A2 (en)	1987-09-02	1989-03-09	Applied Biotechnology, Inc.	Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en)	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
AU648261B2 (en)	1989-08-18	1994-04-21	Novartis Vaccines And Diagnostics, Inc.	Recombinant retroviruses delivering vector constructs to target cells
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
EP2206517B1 (en)	2002-07-03	2023-08-02	Ono Pharmaceutical Co., Ltd.	Immunopotentiating compositions comprising anti-PD-L1 antibodies
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CA2691357C (en) *	2007-06-18	2014-09-23	N.V. Organon	Antibodies to human programmed death receptor pd-1
GB201120527D0 (en) *	2011-11-29	2012-01-11	Ucl Business Plc	Method
PT3702373T (en)	2013-09-13	2022-09-27	Beigene Switzerland Gmbh	Anti-pd1 antibodies and their use as therapeutics and diagnostics
GB201419084D0 (en) *	2014-10-27	2014-12-10	Agency Science Tech & Res	Anti-PD-1 antibodies
MA42447A (en)	2015-07-13	2018-05-23	Cytomx Therapeutics Inc	ANTI-PD-1 ANTIBODIES, ACTIVABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF
CN106699888B (en)	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	PD-1 antibody and preparation method and application thereof
WO2017040790A1 (en)	2015-09-01	2017-03-09	Agenus Inc.	Anti-pd-1 antibodies and methods of use thereof
KR102072317B1 (en)	2015-10-02	2020-01-31	에프. 호프만-라 로슈 아게	Anti-PD1 Antibodies and Methods of Use
US10912287B2 (en)	2016-06-28	2021-02-09	Biocytogen Pharmaceuticals (Beijing) Co., Ltd	Genetically modified mice expressing humanized PD-1
WO2018018031A1 (en) *	2016-07-22	2018-01-25	New York University	Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
NL2017267B1 (en) *	2016-07-29	2018-02-01	Aduro Biotech Holdings Europe B V	Anti-pd-1 antibodies

2018
- 2018-02-23 EP EP18907329.9A patent/EP3755716A4/en active Pending
- 2018-02-23 IL IL276675A patent/IL276675B2/en unknown
- 2018-02-23 JP JP2020544441A patent/JP7110369B2/en active Active
- 2018-02-23 KR KR1020207026905A patent/KR102608723B1/en active Active
- 2018-02-23 WO PCT/CN2018/077016 patent/WO2019161536A1/en not_active Ceased
- 2018-02-23 CN CN201880089110.6A patent/CN112105642B/en active Active
- 2018-02-23 AU AU2018409906A patent/AU2018409906B2/en active Active
- 2018-02-23 CA CA3091502A patent/CA3091502A1/en active Pending
2020
- 2020-07-02 US US16/919,846 patent/US11155625B2/en active Active
2021
- 2021-09-17 US US17/477,889 patent/US20210403570A1/en not_active Abandoned
2024
- 2024-10-04 US US18/906,238 patent/US20250034256A1/en active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014179664A2 (en) *	2013-05-02	2014-11-06	Anaptysbio, Inc.	Antibodies directed against programmed death-1 (pd-1)
WO2016092419A1 (en) *	2014-12-09	2016-06-16	Rinat Neuroscience Corp.	Anti-pd-1 antibodies and methods of use thereof
WO2017019846A1 (en) *	2015-07-30	2017-02-02	Macrogenics, Inc.	Pd-1-binding molecules and methods use thereof
WO2017058115A1 (en) *	2015-09-29	2017-04-06	Asia Biotech Pte. Ltd.	Pd-1 antibodies and uses thereof

Also Published As

Publication number	Publication date
US20210403570A1 (en)	2021-12-30
RU2020130885A3 (en)	2022-03-23
US20250034256A1 (en)	2025-01-30
KR102608723B1 (en)	2023-12-01
WO2019161536A1 (en)	2019-08-29
JP2021517807A (en)	2021-07-29
JP7110369B2 (en)	2022-08-01
US11155625B2 (en)	2021-10-26
US20200332007A1 (en)	2020-10-22
RU2020130885A (en)	2022-03-23
AU2018409906A1 (en)	2020-08-27
KR20200124701A (en)	2020-11-03
IL276675B2 (en)	2023-10-01
AU2018409906B2 (en)	2025-06-05
IL276675A (en)	2020-09-30
CN112105642B (en)	2023-01-31
CA3091502A1 (en)	2019-08-29
EP3755716A1 (en)	2020-12-30
IL276675B1 (en)	2023-06-01
CN112105642A (en)	2020-12-18

Publication	Publication Date	Title
IL279455B2 (en)	2026-01-01	Anti-pd-1 antibodies and uses thereof
TWI799432B (en)	2023-04-21	Anti-ctla-4 antibodies and uses thereof
EP3733704A4 (en)	2021-12-29	Anti-pd-l1 antibody and uses thereof
EP3901172A4 (en)	2023-01-11	Humanized anti-pd-1 antibody and use thereof
EP3755716A4 (en)	2021-08-04	Anti-pd-1 antibodies and uses thereof
EP3997127A4 (en)	2023-08-23	Dll3-targeting antibodies and uses thereof
EP3850012A4 (en)	2022-06-15	Anti-tnfrsf9 antibodies and uses thereof
EP3402520A4 (en)	2019-01-02	Anti-pd-1 antibodies and uses thereof
EP3778635A4 (en)	2022-01-26	Anti-pd-l1 antibody and use thereof
IL283180A (en)	2021-06-30	Anti-pd-1 antibodies and uses thereof
EP3774888A4 (en)	2021-12-29	Anti-phf-tau antibodies and uses thereof
EP3733706A4 (en)	2021-11-03	Anti-pd-l1 antibody and use thereof
EP4041403A4 (en)	2024-02-28	Anti-kir3dl3 antibodies and uses thereof
EP3894439A4 (en)	2022-11-30	Anti-periostin antibodies and uses thereof
EP4025611A4 (en)	2023-10-18	Anti-cxcr2 antibodies and uses thereof
EP3983435A4 (en)	2023-03-08	Anti-talen antibodies and uses thereof
HK40051001A (en)	2021-12-31	Anti-pd-1 antibodies and uses thereof
HK40066149B (en)	2026-02-06	Anti-pd-1 antibodies and uses thereof
HK40012396A (en)	2020-07-24	Anti-pd-l1 antibodies and uses thereof
HK40055005A (en)	2022-03-04	Anti-periostin antibodies and uses thereof
HK40062337A (en)	2022-06-10	Anti-alpha-synuclein antibodies and uses thereof
HK40050823A (en)	2021-12-31	Anti-nkg2a antibodies and uses thereof
HK40060475A (en)	2022-05-20	Anti-npr1 antibodies and uses thereof
HK40052682A (en)	2022-01-21	Anti-il-27 antibodies and uses thereof
HK40058429A (en)	2022-04-22	Anti-tnfr2 antibodies and uses thereof

Legal Events

Date	Code	Title	Description
2019-08-31	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-11-27	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-11-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-12-30	17P	Request for examination filed	Effective date: 20200922
2020-12-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-12-30	AX	Request for extension of the european patent	Extension state: BA ME
2021-04-07	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20210226BHEP Ipc: A61P 35/00 20060101ALI20210226BHEP Ipc: C07K 16/28 20060101AFI20210226BHEP Ipc: A61K 39/39 20060101ALI20210226BHEP Ipc: C12N 15/13 20060101ALI20210226BHEP Ipc: A61P 31/00 20060101ALI20210226BHEP Ipc: A61K 39/395 20060101ALI20210226BHEP Ipc: A61P 37/04 20060101ALI20210226BHEP
2021-06-02	DAV	Request for validation of the european patent (deleted)
2021-06-02	DAX	Request for extension of the european patent (deleted)
2021-08-04	A4	Supplementary search report drawn up and despatched	Effective date: 20210705
2021-08-04	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101AFI20210629BHEP Ipc: C12N 15/13 20060101ALI20210629BHEP Ipc: A61K 39/395 20060101ALI20210629BHEP Ipc: A61P 37/04 20060101ALI20210629BHEP Ipc: A61P 35/00 20060101ALI20210629BHEP Ipc: A61P 31/00 20060101ALI20210629BHEP Ipc: A61K 39/39 20060101ALI20210629BHEP Ipc: A61K 39/00 20060101ALI20210629BHEP